Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Circ Res. 2019 Feb;124(3):437–450. doi: 10.1161/CIRCRESAHA.118.313129

Figure 4. Anti-cytokine Therapy to Reduce Cardiovascular Risk: CANTOS Main Results.

Figure 4.

Cumulative incidence of MACE (myocardial infarction, stroke, or cardiovascular death, left) or MACE+ (myocardial infarction, stroke, hospitalization for unstable angina requiring urgent revascularization, or cardiovascular death, right) in the CANTOS trial. Data are shown for the placebo group and for those in the canakinumab 150mg and 300mg groups. These doses of canakinumab resulted in 35 to 40 percent reductions in hsCRP and interleukin-6 with no effect on LDL cholesterol. Data from Ridker et al, N Engl J Med 2017;377:1119–1131